The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor activator , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://nad1905785.wikiconverse.com/user